May 29, 2025 4:50pm

A lower court decision that put at least a temporary pause on many of President Trump's wide-ranging tariffs was temporarily reversed and submitted to the Supreme Courts … hyping expectation; while Supreme Court limits judges' authority to block infrastructure projects over environmental concerns

Why are unelected judges controlling government policy??

News: Moderna's (MRNA +$0.88) stock rose more than 3% in trading despite an announcement that the National Institutes of Health (NIH), led by Robert F. Kennedy Jr., is ending a $766 M contract to develop its bird flu vaccine as well as the right to purchase this vaccine

Always be vigilant concerning your portfolio … why you need RMi!

Never leave an investor uninformed!  

On point, short on words, long on facts and being judicious!

My mission is to provide clear, actionable guidance on a regular basis to help investors and traders navigate the uncertain and often irrational financial markets.

I put hours of effort to create reporting, while leveraging my 40 years of operating. investigative and research experiences to analyze the key market-moving events and distill that into a cogent outlook.

 

Thursday, RegMed Investors’ (RMi) pre-open: tariff ruling initiates uncertainty and pause, while increasing index and equity swings … https://www.regmedinvestors.com/articles/13937

Wednesday night’s RegMed Investors (RMi) Closing Bell: gains, pain and Fed’s feign to blame inflation … https://www.regmedinvestors.com/articles/13936

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB: HRGN): No partner, No cash, NO runway, extensive liabilities and debts to past employee and university associations … https://www.regmedinvestors.com/articles/13812

 

Thursday: The Dow closed UP +1178.03 points or +0.28%, the S&P closed UP +23.62 points or +0.40% while the Nasdaq closed UP +74.93 points or +0.39%

  • Indexes bumped-up on Wednesday as gains are muted because of trade policy confusion brough-on by non-elected judges

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies

  • Initial claims for unemployment insurance rose more than expected last week. Filings totaled a seasonally adjusted 240,000 for the week ending May 24, up 14,000 from the prior period and ahead of the Dow Jones estimate for 230,000. Continuing claims, which run a week behind, also showed an increase, up 26,000 to the highest level since 11/13/21. Claims rose by 3,329 in Michigan, according to unadjusted figures.
  • GDP (gross domestic product) contracted at a 0.2% pace in Q1, according to numbers adjusted for seasonality and inflation. The number was 0.1% point below the initial estimate and better than the forecast for 0.4%. Most of the decline came from a 42.6% explosion in imports, due to companies trying to get ahead of President Trump’s tariffs.
  • Consumer spending rose a revised 1.2%, compared to the initial estimate of 1.8% and the slowest gain since Q2 of 2023. An upward revision in the gross private domestic investment gain to 24.4% helped offset the consumer slowdown.

Thursday’s advance/decline line opened with a positive 27 incliner, 7 decline and 1 flat ending with a positive close of 24 incliners, 10 decliners and 1 flat    

Metrics:  Thursday, the IBB was up +2.33%, the XBI was up +1.69% while the VIX was down -0.13 points or -0.67% at 19.18

 

Q2/25 – May – 1 market holiday, 9 negative and 11 positive closes

  • April – 11 positive and 10 negative closes

Q1/25

  • March, 10 positive and 12 negative closes
  • February – 12 holiday, 11 negative and 7 positive closes
  • January - 2 holidays, 1 market close, 10 negative and 10 positive closes

 

Thursdays Closing UP (10 of 24) 

  • Blueprint Medicine (BPMC +$7.76 after Wednesday’s -$4.76 after Tuesday -$1.44 after Monday holiday),
  • Alnylam Pharmaceuticals (ALNY +$7.34 after Wednesday’s -$4.54),
  • Ionis Pharmaceuticals (IONS +$1.03 after Wednesday’s -$0.89 after Tuesday +$0.34 after Monday holiday),
  • Moderna (MRNA +$0.88 after Wednesday’s -$0.71 after Tuesday +$0.50 after Monday holiday),
  • Lenz Therapeutics (LENZ +$0.82 after Wednesday’s -$0.69 after Tuesday +$1.23 after Monday's holiday),
  • Ultragenyx Pharmaceuticals (RARE +$0.68 after Wednesday’s -$0.73 after Tuesday -$0.58 after Monday holiday),
  • Regenxbio (RGNX +$0.43 after Wednesday’s -$0.53 after Tuesday -$0.64 after Monday holiday),
  • Verve Therapeutics (VERV +$0.36),
  • Agenus (AGEN +$0.18 after Wednesday’s -$0.53 after Tuesday -$0.27 after Monday holiday),
  • Voyager Therapeutics (VYGR +$0.09),

Flat (1)

  • Homology Medicine (FIXX)

Thursday’s Closing DOWN (10 of 10): 

  • Intellia Therapeutics (NTLA -$2.21 after Wednesday +$0.34),
  • Vericel (VCEL -$0.75 after Wednesday +$0.03 after Tuesday’s +$1.15 after Monday holiday),
  • Beam Therapeutics (BEAM -$0.56),
  • CRISPR Therapeutics (CRSP -$0.44 after Wednesday -$0.35 after Tuesday’s +$0.71 after Monday holiday),
  • Mesoblast (MESO -$0.27),
  • AxoGen (AXGN -$0.06),
  • Editas Medicine (EDIT -$0.04 after Wednesday +$0.22),
  • BioLife Solutions (BLFS -$0.03 after Wednesday’s +$0.09 after Tuesday’s +$0.46 after Monday holiday),
  • bluebird bio (BLUE -$0.01),
  • Prime Medicine (PRME -$0.01),

 

The BOTTOM LINE: Reversers are thye theme of markets and the cell and gene therapy sector ...

  • The cell and gene therapy sector jived on Thursday after diving on Wednesday, urged on Tuesday following Monday’s holiday.

Cell and gene therapy sector equities popped on Tuesday after Monday’s holiday …

  • After getting squashed last Friday after making a barely positive progress on Thursday, unfollowing Wednesday’ negative finish, Tuesday’s following Monday’s positive …

May ‘25: understand the “flow” …

  • 5/29 – Thursday closed positive with 24 positive, 10 negative and 1 flat
  • 5/28 – Wednesday’s closed negative with 7 positive, 26 negative and 2 flats
  • 5/27 – Tuesday closed positive with 21 positive, 11 negative and 3 flats
  • 5/26 – Monday market holiday
  • 5/23 – Friday closed negative with 7 positive, 25 negative and 3 flats
  • 5/22 – Thursday closed positive with 19 positive, 14 negative and 2 flats
  • 5/21 – Wednesday closed negative with 3 positive, 30 negative and 2 flats
  • 5/20 – Tuesday closed positive with 23 positive, 9 negative and 3 flats
  • 5/19 – Monday closed positive with 23 positive, 12 negative and 1 flat
  • 5/16 - Friday closed positive with 29 positive, 3 negative and 3 flats
  • 5/15 – Thursday closed positive with 24 positive, 10 negative and 1 flat
  • 5/14 – Wednesday closed negative with 8 positive, 25 negative and 2 flats
  • 5/13 – Tuesday closed negative with 6 positive, 28 negative and 1 flat
  • 5/12 - Monday positive with 39 positive, 3 negative and 2 flats
  • 5/9 - Friday closed negative with 10 positive, 23 negative and 2 flats
  • 5/8 – Thursday closed positive with 25 positive, 8 negative and 2 flats
  • 5/7 - Wednesday closed positive with 16 positive, 15 negative and 4 flats
  • 5/6 – Tuesday closed negative with 2 positive, 31 negative and 2 flats
  • 5/5 - Monday closed negative with 9 positive, 23 negative and 3 flats
  • 5/2 – Friday closed positive with 24 positive, 8 negative and 3 flats
  • 5/1 - Thursday closed negative with 14 positive, 19 negative and 2 flats

 

I usually write/say “electronic trading and uncle algo” slips in and out, back doors reaping sector disharmony and then pops right back for some profiteering.

  • What can I say, love ‘em, leave ‘em and welcome back to save the sector’s honor – “uncle algo and his electronic dwarfs.”
  • Algos and electronic trading, can’t do with them and can’t do without them <me>

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Thursday: Blueprint Medicine (BPMC), Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS)
  • Wednesday: Intellia Therapeutics (NTLA), BioLife Solutions (BLFS) and Vericel (VCEL)
  • Tuesday: Lenz Therapeutics (LENZ), Vericel (VCEL) and CRISPR Therapeutics CRSP)
  • Monday: Holiday

The worst three (3) in the session: 

  • Thursday:  Intellia Therapeutics (NTLA), Vericel (VCEL) and CRISPR Therapeutics CRSP)
  • Wednesday: Blueprint Medicine (BPMC), Alnylam Pharmaceuticals (ALNY) and Ultragenyx Pharmaceuticals (RARE)
  • Tuesday: Regenxbio (RGNX), Blueprint Medicine (BPMC) and Ultragenyx Pharmaceuticals (RARE)
  • Monday: Holiday

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.